Last edition
News about "positive high-level results"
Imfinzi-Tarlatamab Combination Improves Overall Survival in Phase 3 ES-SCLC Trial
AstraZeneca and Amgen reported statistically significant improvements in overall and progression-free survival with Imfinzi plus tarlatamab versus Imfinzi alone in the Phase 3 DeLLphi-305 trial.
Positive High-level Results | 10/09/2026 | By News Bureau
AstraZeneca's investigational antibody-drug conjugate Sone-Ve demonstrated a significant overall survival benefit in the Phase 3 CLARITY-Gastric01 trial, marking a milestone in the development of targeted therapies for CLDN18.2-positive advanced gastric cancer.
Positive High-level Results | 28/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy